Skip to main content
SpringerLink
Log in

Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

In contrast with the earlier stages and, in particular, the predementia stage, of Alzheimer’s disease (AD), severe dementia is often neglected. However, the advanced stages of dementia are just as important as the earlier stages because of their frequency, their impact on the lives of patients and their caregivers, and their economic consequences. All patients with moderately severe to severe dementia must be evaluated for cognitive, functional, psychological and behavioural symptoms. Thorough and regular evaluation of patients in the advanced stages of the disease has the following objectives: improving patients’ quality of life by encouraging use of their remaining capacities; setting up or modifying a care plan; playing a role in the follow-up of measures instituted; and documenting the natural history of the disease. Therapeutic trials with cholinesterase inhibitors and memantine have been conducted in patients with severe stages of AD. As a consequence, memantine has been approved by numerous drug agencies and donepezil has been approved by the US FDA for use in severe stages of the disease. However, it is important to note that at this stage of AD, and perhaps more than in any other, management must be global and multidisciplinary because of the expression of the disease, its complications and intercurrent disorders. Indeed, thorough knowledge by health professionals of the expression of all disease disorders and intercurrent disorders, and of their significance during the severe stage of AD, is important in the management of these patients to limit complications and facilitate prompt establishment of appropriate care. More effort is needed in both clinical and research settings to ensure that patients with severe AD and their relatives can be offered optimal management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive stage of patients for the clinician. J Psychiatr Res 1975; 12: 189–98

    Article  PubMed  CAS  Google Scholar 

  2. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–9

    PubMed  CAS  Google Scholar 

  3. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity and ordinality. Int Psychogeriatr 1992; 4: 55–69

    Article  PubMed  Google Scholar 

  4. Eastwood R, Reisberg B. Mood and behaviour. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer’s disease. London: Martin Dunitz, 1996: 175–89

    Google Scholar 

  5. Helmer C, Baberger-Gateau P, Dartigues JF. Severe dementia. In: Alzheimer’s disease and cognitive decline, research and practice. Paris: Serdi Edition, 2003: 27–33

    Google Scholar 

  6. Corey-Bloom J. The natural history of Alzheimer’s disease. In: O’Brien J, Ames D, Burns A, editors. Dementia. New York: Oxford University Press, 2000: 405–15

    Google Scholar 

  7. Mirea A, Cummings J. Neuropsychiatric aspects of dementia. In: O)Brien J, Ames D, Burns A, editors. Dementia. New York: Oxford University Press, 2000: 61–79

    Google Scholar 

  8. Wragg R, Jeste D. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989; 146: 577–87

    PubMed  CAS  Google Scholar 

  9. Binetti G, Padovani A, Magni E, et al. Delusions and dementia: clinical and CT correlates. ActaNeurol Scand 1995; 91: 271–5

    CAS  Google Scholar 

  10. Paulsen JS, Salmon DP, Thal TJ, et al. Incidence and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54: 1965–71

    Article  PubMed  CAS  Google Scholar 

  11. Lazarus L, Newton N, Cohler B, et al. Frequency and presentation of depressive symptoms in patients with primary degenerative dementia. Am J Psychiatry 1987; 144: 41–5

    PubMed  CAS  Google Scholar 

  12. Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer’s type. J Am Geriatric Soc 1988; 36: 1–6

    CAS  Google Scholar 

  13. Patel V, Hope T. Aggressive behaviour in elderly people with dementia: a review. Int J Geriatr Psychiatry 1993; 8: 457–72

    Article  Google Scholar 

  14. Eastwood M. Abnormal behaviour associated with dementia. Int Psychiatry Today 1994; 4: 8–10

    Google Scholar 

  15. Sloane PD, Davidson S, Knight N, et al. Severe disruptive vocalizers. J Am Geriatr Soc 1999; 47: 439–45

    PubMed  CAS  Google Scholar 

  16. Franssen EH, Kluger A, Torossian CL, et al. The neurologic syndrome of severe Alzheimer’s disease: relationship to functional decline. Arch Neurol 1993; 50: 1029–39

    Article  PubMed  CAS  Google Scholar 

  17. Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64(12): 2069–73

    Article  PubMed  CAS  Google Scholar 

  18. Auer S, Sclan S, Yaffee RA, et al. The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc 1994; 42: 1266–72

    PubMed  CAS  Google Scholar 

  19. Vellas B, Gillette-Guyonnet S, Nourhashémi F, et al. Falls, frailty and osteoporosis in the elderly: a public health problem. Rev Med Interne 2000; 21: 608–13

    Article  PubMed  CAS  Google Scholar 

  20. Mayeux R, Stern Y, Spanton S, et al. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985; 35: 453–61

    Article  PubMed  CAS  Google Scholar 

  21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–4

    Article  PubMed  CAS  Google Scholar 

  22. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501–9

    PubMed  Google Scholar 

  23. Mitchell SL, Kiely DK, Hamel MB, et al. Estimating prognosis for nursing home residents with advanced dementia. JAMA 2004; 291: 2734–40

    Article  PubMed  CAS  Google Scholar 

  24. Wancata J, Windhaber J, Krautgartner M, et al. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatry Med 2003; 33: 257–71

    Article  PubMed  Google Scholar 

  25. Gillette-Guyonnet S, Nourhashémi F, Andrieu S, et al. The REAL.FR research program on Alzheimer’s disease and its management: methods and preliminary results. J Nutr Health Ageing 2003; 7: 91–6

    CAS  Google Scholar 

  26. Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling Mini Mental State Examination changes in Alzheimer’s disease. Stat Med 2000; 19: 1607–16

    Article  PubMed  CAS  Google Scholar 

  27. Saxton J, McGonigle-Gibson KL, Boiler F, et al. Assessment of the severely impaired patient: description and validation of the new neuropsychological test battery: psychological assessment. J Consult Clin Psychol 1990; 3: 198–303

    Google Scholar 

  28. Gelinas I, Gauthier L, Mclntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the Disability Assessment for Dementia. Am J Occup Ther 1999; 53: 471–81

    Article  PubMed  CAS  Google Scholar 

  29. Galasko B, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1997; 11Suppl. 2: S33–9

    Article  PubMed  Google Scholar 

  30. Katz S, Downs TD, Cash HR, et al. Progress in the development of the index of ADL. Gerontologist 1970; 10: 20–30

    Article  PubMed  CAS  Google Scholar 

  31. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–86

    Article  PubMed  CAS  Google Scholar 

  32. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14

    Article  PubMed  CAS  Google Scholar 

  33. Wood S, Cummings JL, Hsu MA, et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000 Winter; 8(1): 75–83

    Article  PubMed  CAS  Google Scholar 

  34. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989; 44: M77–84

    Article  PubMed  CAS  Google Scholar 

  35. Warshaw G. Assessing physical status in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11: 66–72

    PubMed  Google Scholar 

  36. Teri L, Logsdon RG, McCurry SM. Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002; 86(3): 641–56

    Article  PubMed  Google Scholar 

  37. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649–55

    Article  PubMed  CAS  Google Scholar 

  38. Vellas B, Gauthier S, Allain H, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging 2005; 9: 330–8

    PubMed  CAS  Google Scholar 

  39. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of non-pharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006; 166(20): 2182–8

    Article  PubMed  Google Scholar 

  40. Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007; 55: 158–65

    Article  PubMed  Google Scholar 

  41. Lauque S, Arnaud-Battandier F, Gillette S, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004; 52: 1702–7

    Article  PubMed  Google Scholar 

  42. Gil Gregorio P, Ramirez Diaz SP, Ribera Casado JM; DEMNU Group. Dementia and nutrition: intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 2003; 7: 304–8

    PubMed  CAS  Google Scholar 

  43. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20

    Article  PubMed  CAS  Google Scholar 

  44. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–65

    Article  PubMed  CAS  Google Scholar 

  45. Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20: 559–69

    Article  PubMed  Google Scholar 

  46. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with “advanced moderate” Alzheimer’s disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15: 79–87

    Article  PubMed  CAS  Google Scholar 

  47. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705–12

    Article  PubMed  CAS  Google Scholar 

  48. Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137–48

    Article  PubMed  CAS  Google Scholar 

  49. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41

    Article  PubMed  CAS  Google Scholar 

  50. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–24

    Article  PubMed  CAS  Google Scholar 

  51. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737–44

    Article  PubMed  Google Scholar 

  52. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer’s disease. Prim Care Companion J Clin Psychiatry 2006; 8(3): 158–9

    Article  PubMed  Google Scholar 

  53. Calabrese P, Essner U, Förstl H. The efficacy and tolerability of memantine in AD: a naturalistic study [poster]. 7th International Conference AD/PD; 2005 Mar 9–13; Sorrento

  54. Rainer M, Wuschitz A, Jagsch C, et al. Memantine in Alzheimer’s disease in everyday medical practice [abstract]. World J Biological Psychiatry 2005; 6Suppl. 1: 21

    Google Scholar 

  55. Lesser JM, Hughes S. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer’s disease: definitions and treatment options. Geriatrics 2006 Dec; 61(12): 14–20

    PubMed  Google Scholar 

  56. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD003476

    Google Scholar 

  57. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Eng J Med 2006; 355: 1525–38

    Article  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. Bruno Vellas has grants pending from Pfizer and Eisai. Thierry Voisin has no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. INSERM U825, Alzheimer’s Disease Research Centre (CMRR); F-CMRR-SF, Toulouse University Hospital, Toulouse, France

    Thierry Voisin

  2. INSERM U558, Alzheimer’s Disease Research Centre (CMRR); F-CMRR-SF, Toulouse University Hospital, 170 avenue de Casselardit, 31300, Toulouse, France

    Bruno Vellas

Authors
  1. Thierry Voisin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Vellas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Vellas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voisin, T., Vellas, B. Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. Drugs Aging 26, 135–144 (2009). https://doi.org/10.2165/0002512-200926020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0002512-200926020-00005

Keywords

Search

Navigation